Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Astellas, Dana-Farber Cut Deal on KRAS Inhibitor Development
November 6, 2014
- Astellas Ties Up with US Biotech on Therapies Modulating Unfolded Protein Response
November 6, 2014
- Terumo Seeks Japan Approval of Cell Sheets for Severe Heart Failure
November 6, 2014
- Takeda, Intra-Cellular Therapies End Collaboration on PDE1 Inhibitors
November 6, 2014
- US FDA Advisory Committee Backs Approval of Edoxaban: Daiichi Sankyo
November 6, 2014
- Kyowa Kirin Completes Construction of New Product Manufacturing Facility at Takasaki Plant
November 5, 2014
- Daiichi Sankyo Posts 30.6% Rise in First-Half Operating Profit, 1.7% in Revenue
November 4, 2014
- Sumitomo Dainippon Will Stick to FY2017 Earnings Targets despite BBI608 Setback: Pres.
November 4, 2014
- Astellas’s First-Half Sales Rise 9.3%, Operating Profit 61.8%
November 4, 2014
- Fujifilm to Take Majority Stake in Regenerative Medicine Startup J-TEC
November 4, 2014
- Bayer Seeks New Indications for Antibiotic Ciproxan
November 4, 2014
- AnGes MG to Initiate Multinational PIII Study of Collategene in Europe
November 4, 2014
- Takeda Aims for Consecutive Sales Growth through FY2022
October 31, 2014
- Sumitomo Dainippon’s Sales Down 1.7% on Drug Price Cuts in Japan
October 31, 2014
- Eisai Flounders in Japan, US Markets, Half-Year Profits Dive 60%
October 31, 2014
- Takeda Reports 2.8% Rise in First-Half Sales
October 31, 2014
- MTPC Files Remicade for Behcet’s Disease with Special Lesions
October 31, 2014
- Smaller Crestor Royalties Send Shionogi’s April-Sept. Sales Lower
October 30, 2014
- MTPC’s Half-Year Sales Dip, but Operating Profit Jumps on Gilenya Royalties
October 30, 2014
- Chugai to Supply Tamiflu for 7 Million Persons This Flu Season
October 30, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…